Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Martina Schneider(Valneva (Austria)), Nina Wressnigg(Valneva (Austria)), Romana Hochreiter(Valneva (Austria)), Robert P. McMahon(Valneva (Austria)), Susanne Eder-Lingelbach(Valneva (Austria)), Karin Kosulin(Valneva (Austria)), Sebastian Toepfer(Valneva (Austria)), Ulrike Fuchs(Valneva (Austria)), Robert M. Mader(Valneva (Austria)), Vera Buerger(Valneva (Austria)), Julian Larcher‐Senn, Katrin Dubischar(Valneva (Austria)), Marivic Narciso-Abraham(Valneva (Austria)), Sandra Hadl(Valneva (Austria)), Annegret Bitzer(Valneva (Austria)), Juan-Carlos Jaramillo(Valneva (Austria)), Oliver Zoihsl(Valneva (Austria))
The Lancet
June 1, 2023
Cited by 218


Related Papers